Accessing Necessary Arthritis Medications: A Pan-Canadian Analysis

Name: Accessing Necessary Arthritis Medications: A Pan-Canadian Analysis
SKU: 10608-0405-WEB
Availability: InStock

Health

February 5, 2020

Health and Healthcare

Author: Junyi Feng, Monika Slovinec D’Angelo, Nigel Russell

$0.00

Canadians spent $1.9 billion on 16.5 million claims for arthritis drugs in 2017.

Some medically necessary drugs are virtually unaffordable for those without private insurance, due to high out-of-pocket costs.

Public access to new and innovative arthritis medications is limited. While private programs have access to all 79 medications used to treat arthritis, public programs provide access to 72.

Canadians spent $1.9 billion on 16.5 million claims for arthritis drugs in 2017.

Some type of health system reform is needed to improve the access, affordability, and consistency in coverage of arthritis drugs across the country.

Want a discount? Become a member by purchasing a subscription! Learn More

While arthritis affects nearly one in five Canadian adults, their access to vital medications varies widely across the country. This impact paper highlights discrepancies in arthritis drug coverage across provinces, jurisdictions, and insurance plans.